SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Morria Biopharmaceuticals Plc Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug